Vávrová, J <br/><br/>
Ex vivo expansion CD34+/AC133+-selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy.  [electronic resource] 

 -  Hematology and cell therapy  Jun 1999 
 - 105-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1269-3286 
<br/><br/><label>Standard No.: </label>10.1007/s00282-999-0105-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AC133 Antigen<br/>Adult<br/>Antigens, CD<br/>Antigens, CD34--blood<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Cell Division--drug effects<br/>Cyclophosphamide--administration & dosage<br/>Epirubicin--administration & dosage<br/>Female<br/>Glycoproteins--blood<br/>Hematopoietic Stem Cells--cytology<br/>Humans<br/>Injections, Subcutaneous<br/>Interleukin-11--pharmacology<br/>Interleukin-3--pharmacology<br/>Middle Aged<br/>Peptides--blood<br/>Stem Cell Factor--pharmacology